AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure
There are no recent dividends present for ATRC.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.